• AAPL 195.71
  • TSLA 243.84
  • AMZN 147.42
  • BTC-USD 43952.582
  • ETH-USD 2352.6055
  • EURUSD 1.0764
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. ASND.US

Ascendis Pharma AS (ASND NASDAQ) stock market data APIs

$107.67 -0.02(-0%) as of December 8, 2023

Ascendis Pharma AS Financial Data Overview

107.69
107.67
-
111.41
106.49
64.33-127.77
6 090 M
56 547 K
152 M
-2.88
0
0.51
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ASND',
Type: 'Common Stock',
Name: 'Ascendis Pharma AS',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG007R7VNC1',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2015-01-28',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Ascendis Pharma AS Fundamental Data is available in our Financial Data APIs

  • Net Revenue 152 M
  • EBITDA -559 929 024
  • Earnings Per Share -11.54
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Ascendis Pharma AS Earnings via APIs

  • Latest Release 2023-11-07
  • EPS/Forecast -2.38

Get Ascendis Pharma AS End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Ascendis Pharma AS latest news via APIs

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

–   Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan –   Ascendis Pharma is eligible to receive $70 mill...
  • ASCENDIS PHARMA
  • HEALTH
  • LICENSING AGREEMENTS
  • NASDAQ:ASND
  • PARTNERSHIPS

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

Ascendis Pharma –   Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan –   Ascendis Pharma is eligible to...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com